Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Hims & Hers vs Neo Soma Healthcare

By GLP-1 ScorecardUpdated

Hims & Hers
Site position #56

Higher grade

Neo Soma Healthcare
Site position #236

Lower grade

Score comparison

Hims & Hers has the higher recorded score — 75.6/100 to 65.8/100.

Hims & Hers grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Mass-market app-first program with nationwide reach and consumer-grade polish.

We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.

Factor by factor

These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.

Cost valueHims & Hers +16
82
66
Dose & formulationHims & Hers +6
78
72
Clinical oversightNeo Soma Healthcare +17
55
72
Labs & monitoringHims & Hers +18
80
62
FulfillmentHims & Hers +27
84
57
Contract termsHims & Hers +25
80
55
Hims & Hers · top barNeo Soma Healthcare · bottom bar

The numbers

Swipe or scroll to compare both providers.

MetricHims & HersNeo Soma Healthcare
WeighScore75.6/10065.8/100
GradeCC
Site position#56#236
Semaglutide$199/mo$199/mo
TirzepatideNot disclosed$330/mo
CoverageAll 50 statesCoverage not published
Brand-name accessNot confirmedNot confirmed
Oral / sublingualNot confirmedNot confirmed
Hims & Hers

Site position #56 · C

FDAWarning letter issued to Hims & Hers Health, Inc. dba Hims in September 2025. See the FDA warning-letter database.

Strengths

  • Nationwide
  • Polished app
  • Strong brand trust

What to consider

  • Tirzepatide pricing inconsistently disclosed
  • Industry-wide compounding scrutiny
Neo Soma Healthcare

Site position #236 · C

Strengths

  • LegitScript verification badge present
  • Publishes the FDA compounded-medication disclaimer
  • Pricing shown publicly for all 6 product lines
  • Multi-product platform (GLP-1, sexual health, peptide therapies)
  • First-month discount on semaglutide ($99 entry)

What to consider

  • Pharmacy partner not named (503A vs 503B unclear)
  • States served not listed — no per-state availability table
  • No named medical director
  • Standard semaglutide pricing ($199/mo) above the cheapest providers ($150–180/mo)
  • Tirzepatide entry pricing ($330) above the cheapest providers (~$200–250/mo)

Featured provider

CoreAge Rx

CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.

Commercial relationships affect this placement. The score comparison above is separate.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard